Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
1987
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01DB07
|
| gptkbp:blackBoxWarning |
gptkb:secondary_leukemia
cardiotoxicity |
| gptkbp:CASNumber |
65271-80-9
|
| gptkbp:developedBy |
gptkb:Immunex
|
| gptkbp:drugClass |
antineoplastic agent
immunosuppressant |
| gptkbp:genericName |
gptkb:mitoxantrone
|
| gptkbp:hasMolecularFormula |
C22H28N4O6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Novantrone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
DNA intercalation
topoisomerase II inhibition |
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting hair loss cardiotoxicity |
| gptkbp:synonym |
mitoxantrone hydrochloride
|
| gptkbp:usedFor |
gptkb:acute_myeloid_leukemia
prostate cancer multiple sclerosis |
| gptkbp:bfsParent |
gptkb:mitoxantrone
|
| gptkbp:bfsLayer |
7
|